Literature DB >> 19731165

Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose.

Tania Mieke Robertson1, Gregory W Hendey, Geoff Stroh, Marc Shalit.   

Abstract

OBJECTIVE: To compare the prehospital time intervals from patient contact and medication administration to clinical response for intranasal (IN) versus intravenous (IV) naloxone in patients with suspected narcotic overdose.
METHODS: This was a retrospective review of emergency medical services (EMS) and hospital records, before and after implementation of a protocol for administration of intranasal naloxone by the Central California EMS Agency. We included patients with suspected narcotic overdose treated in the prehospital setting over 17 months, between March 2003 and July 2004. Paramedics documented dose, route of administration, and positive response times using an electronic record. Clinical response was defined as an increase in respiratory rate (breaths/min) or Glasgow Coma Scale score of at least 6. Main outcome variables included time from medication to clinical response and time from patient contact to clinical response. Secondary variables included numbers of doses administered and rescue doses given by an alternate route. Between-group comparisons were accomplished using t-tests and chi-square tests as appropriate.
RESULTS: One hundred fifty-four patients met the inclusion criteria, including 104 treated with IV and 50 treated with IN naloxone. Clinical response was noted in 33 (66%) and 58 (56%) of the IN and IV groups, respectively (p = 0.3). The mean time between naloxone administration and clinical response was longer for the IN group (12.9 vs. 8.1 min, p = 0.02). However, the mean times from patient contact to clinical response were not significantly different between the IN and IV groups (20.3 vs. 20.7 min, p = 0.9). More patients in the IN group received two doses of naloxone (34% vs. 18%, p = 0.05), and three patients in the IN group received a subsequent dose of IV or IM naloxone.
CONCLUSIONS: The time from dose administration to clinical response for naloxone was longer for the IN route, but the overall time from patient contact to response was the same for the IV and IN routes. Given the difficulty and potential hazards in obtaining IV access in many patients with narcotic overdose, IN naloxone appears to be a useful and potentially safer alternative.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19731165     DOI: 10.1080/10903120903144866

Source DB:  PubMed          Journal:  Prehosp Emerg Care        ISSN: 1090-3127            Impact factor:   3.077


  18 in total

Review 1.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

2.  A response to the opioid overdose epidemic: naloxone nasal spray.

Authors:  Daniel P Wermeling
Journal:  Drug Deliv Transl Res       Date:  2013-02-01       Impact factor: 4.617

3.  Disparity in naloxone administration by emergency medical service providers and the burden of drug overdose in US rural communities.

Authors:  Mark Faul; Michael W Dailey; David E Sugerman; Scott M Sasser; Benjamin Levy; Len J Paulozzi
Journal:  Am J Public Health       Date:  2015-04-23       Impact factor: 9.308

Review 4.  Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access.

Authors:  Daniel P Wermeling
Journal:  Ther Adv Drug Saf       Date:  2015-02

5.  Pharmacokinetics of a new, nasal formulation of naloxone.

Authors:  Ida Tylleskar; Arne Kristian Skulberg; Turid Nilsen; Sissel Skarra; Phatsawee Jansook; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2017-01-31       Impact factor: 2.953

Review 6.  Flumazenil, naloxone and the 'coma cocktail'.

Authors:  Marco L A Sivilotti
Journal:  Br J Clin Pharmacol       Date:  2015-09-21       Impact factor: 4.335

7.  Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl.

Authors:  Joseph Carpenter; Brian Patrick Murray; Sukhshant Atti; Tim P Moran; Arthur Yancey; Brent Morgan
Journal:  J Med Toxicol       Date:  2019-08-30

8.  Multiple Naloxone Administrations Among Emergency Medical Service Providers is Increasing.

Authors:  Mark Faul; Peter Lurie; Jeremiah M Kinsman; Michael W Dailey; Charmaine Crabaugh; Scott M Sasser
Journal:  Prehosp Emerg Care       Date:  2017-05-08       Impact factor: 3.077

9.  Use of Naloxone by Emergency Medical Services during Opioid Drug Overdose Resuscitation Efforts.

Authors:  Steven Allan Sumner; Melissa C Mercado-Crespo; M Bridget Spelke; Leonard Paulozzi; David E Sugerman; Susan D Hillis; Christina Stanley
Journal:  Prehosp Emerg Care       Date:  2015-09-18       Impact factor: 3.077

10.  Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.

Authors:  Abby M Bailey; Daniel P Wermeling
Journal:  Ann Pharmacother       Date:  2014-02-12       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.